S

Sage Therapeutics
D

SAGE

8.80500
USD
0.04
(0.46%)
مغلق
حجم التداول
104,460
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
551,389,079
أصول ذات صلة
A
ACAD
0.190
(0.82%)
23.250 USD
ALNY
ALNY
1.29
(0.39%)
329.01 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
INCY
INCY
-0.300
(-0.43%)
70.180 USD
I
IONS
0.100
(0.24%)
42.240 USD
O
OPK
-0.03000
(-2.15%)
1.36500 USD
REGN
REGN
-1.20
(-0.21%)
563.22 USD
VRTX
VRTX
-2.89
(-0.61%)
469.58 USD
المزيد
الأخبار المقالات

العنوان: Sage Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.